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Patients with
Definite or
Probable
Stent
Thrombosis
No Stent
Thrombosis P value
vents Under 30 Days: n74 n2923
Confirmed Discontinuation
of Thienopyridine
2/65 (3.08%) 54/2794 (1.93%) 0.37
Confirmed Discontinuation
of Aspirin
3/65 (4.62%) 59/2789 (2.12%) 0.17
Confirmed Discontinuation
of Thienopyridine or
Aspirin
5/65 (7.69%) 106/2795 (3.79%) 0.11
Confirmed Discontinuation
on Both Aspirin and
Thienopyridine
0/60 (0%) 7/2696 (0.26%) 1
Events From 30 Days to
6 months:
n15 n2908
Confirmed Discontinuation
of Thienopyridine
5/13 (38.5%) 204/2704 (7.54%) 0.002
Confirmed Discontinuation
of Aspirin
5/13 (38.5%) 65/2701 (2.41%) 0.0001
Confirmed Discontinuation
of Thienopyridine or
Aspirin
7/13 (53.8%) 250/2704 (9.25%) 0.0001
Confirmed Discontinuation
on Both Aspirin and
Thienopyridine
3/9 (33.3%) 19/2473 (0.77%) 0.0001
Events From 6 to 12
months:
n13 n2895
Confirmed Discontinuation
of Thienopyridine
6/12 (50.0%) 767/2661 (28.8%) 0.18
Confirmed Discontinuation
of Aspirin
0/11 (0%) 75/2660 (2.82%) 1
Confirmed Discontinuation
of Thienopyridine or
Aspirin
6/12 (50.0%) 803/2662 (30.2%) 0.20
Confirmed Discontinuation
on Both Aspirin and
Thienopyridine
0/6 (0%) 39/1898 (2.05%) 1
Events Beyond 1 year: n45 n2850
Confirmed Discontinuation
of Thienopyridine
11/36 (30.6%) 1662/2599 (63.9%) 0.0001
Confirmed Discontinuation
of Aspirin
5/37 (13.5%) 89/2594 (3.43%) 0.009
Confirmed Discontinuation
of Thienopyridine or
Aspirin
14/37 (37.8%) 1697/2599 (65.3%) 0.0008
Confirmed Discontinuation
on Both Aspirin and
Thienopyridine
2/25 (8.00%) 54/956 (5.65%) 0.65
Conclusions: In the HORIZONS-AMI trial of patents with STEMI undergoing stent
implantation, the relationship between ST and non-usage of DAPT was complex and
varied overtime. It was strong during the 1-6 month timeframe, but not between 6 and 12
months. Hereafter, very late ST was associated with non-usage of aspirin but not of a
thienopyridine.
TCT-490
Coronary Artery Disease and Tako-tsubo Cardiomyopathy: a Possible
Association
Guido Parodi1, Rodolfo Citro2, Benedetta Bellandi1, Eduardo Bossone2,
Stefano Del Pace1, Marco Marrani1, Fausto Rigo3, Francesco Bovenzi4,
Renato Valenti1, David Antoniucci1
1Careggi Hospital, Florence, Italy, 2San Giovanni di Dio e Ruggi d’Aragona,
Salerno, Salerno, 3Ospedale dell’Angelo, Mestre, Mestre, 4Ospedale campo di
Marte, Lucca, Lucca
Background: In the medical literature several cases of Tako-tsubo cardiomyopathy
(TTC) with critical coronary artery disease (CAD) has been reported, and in the clinical
practice several typical TTC cases shown significant stenosis of coronary arteries that
cannot be related to the dysfunctional myocardium. The aim of this study is to evaluate
the prevalence, clinical characteristics and outcome of patients with TTC and critical CAD
in a large multicentre database.
Methods: In the 26 participating centers, 450 patients admitted with the diagnosis of TTC
(modified Mayo Criteria) underwent coronary angiography within 48 hours of hospital
admission and were progressively included in the Tako-tsubo Italian Network (TIN)
Registry.
Results: Overall, 43 (9.6%) patients had at least 1 critical coronary stenosis ( 50%) not
supplying the dysfunctional myocardium, or a previous myocardial revascularization
(percutaneous or surgical), while 407 (90.4%) had not critical stenosis or truly normal
coronary arteries. TTC patients with critical CAD were more likely to have advanced age,
diabetes, familiar history of CAD, acute functional mitral regurgitation and a delayed left
ventricular function recovery as compared with those without. At 6-month follow-up, the
incidence of death, TTC recurrence and rehospitalization rates were similar between
patients with critical CAD and patients with normal coronary arteries (Table). At
multivariable Cox analysis, independent predictors of death were Charlson comorbidity
index while the presence of CAD did not significantly influence mid-term outcome.
Variable
TTC Patients (n450)
p value
Critical CAD Not critical CAD
n43 (9.6%) n407 (90.4%)
Chest pain 1 (2%) 14 (4%) 0.693
Dyspnoea 4 (10%) 14 (4%) 0.067
TTC recurrence 0 (0%) 1 (0.3%) 0.739
Rehospitalization 5 (12%) 23 (6%) 0.152
Cardiac causes 3 (7%) 11 (3%) 0.146
Non cardiac causes 2 (5%) 12 (3%) 0.584
Death 2 (5%) 11 (3%) 0.504
Cardiac causes 1 (2%) 5 (1%) 0.579
Non cardiac causes 1 (2%) 6 (2%) 0.698
Conclusions: The presence of significant CAD is a possible finding in a not trivial
proportion of patients with TTC. Thus, when the the stenotic artery does not supply the
dysfunctional myocardium, the presence of angiographically significant CAD should not
be considered an exclusion criteria for TTC.
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Background: Primary percutaneous coronary intervention (PPCI) is currently the
treatment of choice for patients presenting with ST-segment elevation acute myocardial
infarction (STEMI). The purpose of the present study is to determine the incidence and
predictors of 30 days mortality in elderly patients with STEMI treated with PPCI.
Methods: Prospective observational study. Consecutive patients older than 75 years with
STEMI undergoing PPCI in our Hospital were enrolled between January 2006 to
December 2009. Prior PPCI, patients received loading dose of 300 mg Clopidogrel and
325-500 mg of Aspirin. Unfractionated Heparin was administered according to current
guidelines. Abxicimab was administered at physician’s discretion. Statistical analysis was
performedwith SPSS v.18.
Results: Among 1,619 STEMI patients admitted for PPCI, 369(22.8%) were older than
75 years. Mean age was 80.1 3.9 years, 196(53.1%) male patients, 90 (24.4%) diabetes
mellitus, 51 (13.8%) prior myocardial infarction, 11 (3%) prior congestive heart failure,
30 (8.3%) in Killip class III-IV, 315  238 minutes mean time of symptoms onset to
PPCI. 30 days all-cause mortality occurred in 58 (16.4%) patients and cardiac mortality
in 53 (15.1%). Univariate analysis determined age older than 81.3 years, non loading dose
of Aspirin and Clopidogrel prior PPCI, Killip class 3-4 presentation, final TIMI grade flow
less than 3 and prior congestive heart failure as predictors of 30 days mortality. A
multivariate logistic regression analysis was performed, identifying as independent
predictors of 30 days mortality Killip class 3-4 and final TIMI grade flow less than 3.
Conclusions: Among patients older than 75 years with STEMI undergoing PPCI in our
center, 30 days all-cause mortality was 16.4%, mainly due to cardiac causes(15.1%). Only
Killip class 3-4 and final TIMI grade flow less than 3 were identified as independent
predictors of 30 days mortality.
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